Inimmune
PrivateLast Round
Grant
Feb 1, 2024
Total Funding Raised
$46.58M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Inimmune is a biotechnology company that discovers and develops novel immunotherapeutics and vaccine adjuvants for the treatment of allergy, autoimmunity, infectious diseases, and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Inimmune Comparables
Compare Inimmune with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adjuvance Technologies | 87% | |
| Access to Advanced Health Institute | 81% | |
| Dynavax Technologies Corporation | 66% | |
Inimmune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 1, 2024 | ||||
| Series A | Jul 9, 2020 | ||||
| Grant | Jul 1, 2020 | ||||
| Grant | Jun 25, 2018 | ||||
| Grant | Feb 14, 2018 |
Key People
Founding team and executive leadership
Inimmune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| NIH RADx | Grant |
| Two Bear Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 5, 2026
Ryan McMillian appointed to lead financial strategy.
- Mar 5, 2026
Appointed Ferdinand Massari, M.D. as new Chief Medical Officer.
Inimmune Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Inimmune's valuation, stock price, and market status.